Clinical Trial Update: Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC [Phase 1]

View source ↗

Summary

Phase I study of α-PD-L1/DLL3 CAR-T therapy in patients with relapsed/refractory small cell lung cancer (extensive stage) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• α-PD-L1/DLL3 CAR-T

Snippet

Sponsor: Sichuan University | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 1 | Status: RECRUITING